| Revenue growth | 22% YoY in Q4FY26; 14.5% for FY26. |
|---|---|
| Margins | Q4 Adjusted EBITDA margin at 30%; targeting mid-teen EBITDA for Cenexi. |
| Order book | Current order book supports 12-13% FY27 growth guidance. |
| Demand visibility | Strong order book and forecast; high demand for new launches. |
| Management confidence | High confidence in sustaining momentum and mid-term growth targets. |
Growth
FY26 revenue grew 14.5% to INR 64,307M. US market grew 26% in Q4 and 11% for the full year.
Outlook
Guided 12-13% constant currency growth for FY27; INR 2,000Cr capex planned over next three years.
Risks
Supply chain issues in Middle East caused a 1-2% revenue impact; potential 5-6% cost increase in glass/vials.
Earnings Call filed with NSE, NSE: GLAND. Summary written with AI assistance from the document.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,159.00
- Market cap
- ₹52,127 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 46.2×Sector 47.4×
- Promoter holding
- 51.77%-0.06% QoQ
- FII holding
- 8.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Merger & Restructuring Worth ₹4.81 Cr
Gland Pharma is acquiring Gland Pharma USA Inc. for ₹4.81 Crore to streamline its corporate structure by making it a direct wholly-owned subsidiary.
- Value
- ₹4.81 Cr
Gland Pharma Acquisition Worth ₹4.76 Cr
Gland Pharma approved acquiring its step-down subsidiary, Gland Pharma USA Inc., from another wholly-owned subsidiary to streamline corporate structure. The transaction costs USD 5,01,208.
- Value
- ₹4.76 Cr
- Execution
- By October 31, 2026
Gland Pharma Employee Stock Options
Gland Pharma Limited granted 5,90,249 employee stock options to 124 employees under its ESOP 2025 scheme. These options are subject to specified vesting schedules and pricing.
Gland Pharma Legal & Regulatory
Gland Pharma paid fines totaling ₹1.40 Lakh to NSE and BSE for a technical regulatory non-compliance breach. The company has since ensured compliance with shareholder approval.
- Value
- ₹0.14 Cr
Gland Pharma Promoter Selling
Fosun Pharma Industrial Pte. Ltd., a promoter, sold 98,97,000 Gland Pharma shares in the open market. Its stake fell from 51.76% to 45.76%.
Gland Pharma Business Update
Gland Pharma announced that the USFDA completed a routine GMP inspection of its Visakhapatnam facility with zero Form 483 observations.